In the United States, there are currently around 100 active and recruiting clinical trials researching new treatment methods for people living with NASH, including several collaborative efforts between clinical development companies and societies. The necessity of clinical research becomes clear when looking at the millions of people in the United States living with fatty liver disease of which 20% also live with NASH. Last year, there have been different cases of new potential treatment developments, which we will introduce today.
New LiverMultiScan mapping tool to identify NASH
According to Perspectum Diagnostics, their newest version of a LiverMultiScan magnetic resonance imaging technology can identify the nonalcoholic fatty liver disease as well as nonalcoholic steatohepatitis (NASH). Through this new learning with machine learning-based automatic segmentation, the researcher will now be able to identify silent diseases such as NASH faster, which means treatment can also be earlier.
Thyroid receptor showing response in NASH
According to the University of Oxford, a new thyroid receptor agonist (MGL 3196) has shown a sustained reduction in fat in the liver and other markers such as atherogenic lipids as well as serum liver transferases all associated with NASH. The clinical trial showed that there was a statistically significant resolution of NASH in correlation with the reduction of liver fat. These findings were identified in a 36-week research study and researchers are now ready to move on to a phase 3 trial with this evidence to continue testing the receptor.
Aramchol can improve histology in NASH through liver fat reduction
Aramchol, a stearoyl coenzyme desaturate A inhibitor has been found to reduce liver fat in a one-year 2b clinical trial. The inhibitor seems to also improve histology and has proven to be safe and tolerable for patients with nonalcoholic fatty liver disease. According to the Sorbonne University France, Aramchol has shown not only the reduction of fat but also biochemical improvements, NASH resolution, and fibrosis reduction.
Make a difference for you and your health community
Looking at new developments of the last year in regard to NASH shows how essential clinical trials are for medical innovation. To find new treatments, clinical trials need volunteers to improve the quality of life for people living with NASH. Sounds interesting? Sign up here and become part of medical history.
Comments